1. Home
  2. KBH vs CELC Comparison

KBH vs CELC Comparison

Compare KBH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KB Home

KBH

KB Home

HOLD

Current Price

$51.96

Market Cap

3.8B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$120.01

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBH
CELC
Founded
1957
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.1B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
KBH
CELC
Price
$51.96
$120.01
Analyst Decision
Hold
Strong Buy
Analyst Count
14
8
Target Price
$56.17
$107.88
AVG Volume (30 Days)
1.3M
643.5K
Earning Date
03-24-2026
05-13-2026
Dividend Yield
1.92%
N/A
EPS Growth
N/A
N/A
EPS
0.52
N/A
Revenue
$4,547,002,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.60
$740.70
P/E Ratio
$99.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$48.17
$9.50
52 Week High
$68.71
$125.00

Technical Indicators

Market Signals
Indicator
KBH
CELC
Relative Strength Index (RSI) 44.65 57.58
Support Level $48.89 $99.38
Resistance Level $66.32 N/A
Average True Range (ATR) 1.68 6.11
MACD 0.43 0.91
Stochastic Oscillator 69.98 77.26

Price Performance

Historical Comparison
KBH
CELC

About KBH KB Home

KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: